Wedbush Weighs in on Apellis Pharmaceuticals, Inc.'s FY2026 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities research analysts at Wedbush lowered their FY2026 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a report released on Tuesday, May 7th. Wedbush analyst L. Chico now expects that the company will post earnings of $4.29 per share for the year, down from their prior forecast of $4.50. Wedbush currently has a "Neutral" rating and a $57.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.27) per share.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) EPS for the quarter, hitting analysts' consensus estimates of ($0.54). Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company had revenue of $172.33 million for the quarter, compared to analysts' expectations of $163.37 million. During the same quarter in the previous year, the firm posted ($1.56) EPS. Apellis Pharmaceuticals's revenue was up 284.3% on a year-over-year basis.

Several other brokerages have also commented on APLS. Jefferies Financial Group raised Apellis Pharmaceuticals from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $68.00 to $80.00 in a report on Monday, February 5th. HC Wainwright reiterated a "buy" rating and issued a $92.00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday. Needham & Company LLC reissued a "buy" rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a research note on Wednesday. Citigroup lowered their target price on Apellis Pharmaceuticals from $67.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, Raymond James lifted their price target on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a "strong-buy" rating in a research report on Thursday, January 11th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $76.67.

Apellis Pharmaceuticals Price Performance

Shares of APLS stock traded up $0.22 on Thursday, reaching $42.52. The company's stock had a trading volume of 1,052,329 shares, compared to its average volume of 1,574,091. The company has a market capitalization of $5.16 billion, a P/E ratio of -9.44 and a beta of 0.97. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. The stock's 50 day simple moving average is $54.30 and its 200-day simple moving average is $57.42. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the sale, the insider now owns 1,115,983 shares of the company's stock, valued at approximately $60,452,799.11. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Timothy Eugene Sullivan sold 4,000 shares of the firm's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $58.66, for a total transaction of $234,640.00. Following the completion of the transaction, the chief financial officer now owns 93,338 shares of the company's stock, valued at $5,475,207.08. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Pascal Deschatelets sold 69,107 shares of the company's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares in the company, valued at $60,452,799.11. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 376,427 shares of company stock worth $23,169,639. Insiders own 7.50% of the company's stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Orion Portfolio Solutions LLC raised its position in Apellis Pharmaceuticals by 37.1% during the first quarter. Orion Portfolio Solutions LLC now owns 27,079 shares of the company's stock valued at $1,592,000 after acquiring an additional 7,330 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Apellis Pharmaceuticals by 11.6% during the 1st quarter. ProShare Advisors LLC now owns 8,452 shares of the company's stock worth $497,000 after purchasing an additional 881 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Apellis Pharmaceuticals by 1,300.8% during the 1st quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company's stock valued at $211,000 after purchasing an additional 3,330 shares in the last quarter. Sei Investments Co. lifted its stake in shares of Apellis Pharmaceuticals by 57.4% in the 1st quarter. Sei Investments Co. now owns 39,864 shares of the company's stock valued at $2,343,000 after purchasing an additional 14,531 shares during the period. Finally, Lisanti Capital Growth LLC boosted its holdings in Apellis Pharmaceuticals by 92.7% during the first quarter. Lisanti Capital Growth LLC now owns 89,210 shares of the company's stock worth $5,244,000 after buying an additional 42,905 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).